SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Sets Nov 16 Panel For Human Genome Sciences, Inc. And GlaxoSmithKline Lupus Drug; Benlysta Would be First New Lupus Drug in 50 Years

September 13, 2010 | 
1 min read

CHICAGO, Sept 13 (Reuters) - A committee advising the U.S. Food and Drug Administration will discuss GlaxoSmithKline Plc (GSK.L) and Human Genome Sciences’ (HGSI.O) anticipated lupus drug Benlysta on Nov 16.

Regulatory
GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
December 9, 2024
 · 
7 min read
 · 
Tristan Manalac